同型半胱氨酸与小血管性卒中的孟德尔随机化分析
本研究采用孟德尔随机化方法,利用与总同型半胱氨酸(tHcy)、叶酸、维生素B6和维生素B12相关的单核苷酸多态性(SNP)数据,结合MEGASTROKE联盟的卒中亚型数据进行分析。结果显示,遗传预测的tHcy升高与小血管性卒中相关,而与大动脉粥样硬化性或心源性卒中无关;遗传预测的叶酸和维生素B6升高与小血管性卒中风险降低相关。
要点
- 遗传预测的tHcy每升高1个标准差,小血管性卒中风险增加,OR为1.34。
- 该关联主要由MTHFR和MUT基因附近的SNP驱动。
- 遗传预测的叶酸和维生素B6升高与小血管性卒中风险降低相关。
核心结论
- 遗传预测的tHcy升高选择性地与小血管性卒中相关,而与其它卒中亚型无关。
- 降低同型半胱氨酸的治疗对卒中的预防作用可能仅限于小血管性卒中亚型。
研究设计与样本
- 采用孟德尔随机化分析,使用与tHcy(n=18)、叶酸(n=3)、维生素B6(n=1)、维生素B12(n=14)相关的SNP数据。
- 卒中数据来自MEGASTROKE联盟,包括16,952例亚型分型的缺血性卒中病例和404,630例非病例。
主要发现
- 遗传预测的tHcy每升高1个标准差,小血管性卒中的OR为1.34(95%CI 1.13-1.58;p=6.7×10-4)。
- 遗传预测的tHcy与大动脉粥样硬化性或心源性卒中无关联。
- 遗传预测的叶酸每升高1个标准差,小血管性卒中的OR为0.49(95%CI 0.34-0.71;p=1.3×10-4)。
- 遗传预测的维生素B6每升高1个标准差,小血管性卒中的OR为0.70(95%CI 0.52-0.94;p=0.02)。
- 遗传预测的维生素B12升高与任何卒中亚型均无关联。
临床怎么用
- 提示降低同型半胱氨酸的治疗在卒中预防中的效果可能局限于小血管性卒中亚型。
- MTHFR和MUT基因附近变异是否通过同型半胱氨酸以外通路影响小血管性卒中风险尚需进一步研究。
局限性
- MTHFR和MUT基因附近遗传变异是否通过同型半胱氨酸水平及下游效应以外的通路影响小血管性卒中风险,尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Trials of B vitamin therapy to lower blood total homocysteine (tHcy) levels for prevention of stroke are inconclusive. Secondary analyses of trial data and epidemiological studies suggest that tHcy levels may be particularly associated with small vessel stroke (SVS). We assessed whether circulating tHcy and B vitamin levels are selectively associated with SVS, but not other stroke subtypes, using Mendelian randomization. METHODS: We used summary statistics data for single-nucleotide polymorphisms (SNPs) associated with tHcy (n = 18), folate (n = 3), vitamin B6 (n = 1), and vitamin B12 (n = 14) levels, and the corresponding data for stroke from the MEGASTROKE consortium (n = 16,952 subtyped ischemic stroke cases and 404,630 noncases). RESULTS: Genetically predicted tHcy was associated with SVS, with an odds ratio of 1.34 (95% confidence interval [CI], 1.13-1.58; p = 6.7 × 10-4 ) per 1 standard deviation (SD) increase in genetically predicted tHcy levels, but was not associated with large artery or cardioembolic stroke. The association was mainly driven by SNPs at or near the MTHFR and MUT genes. The odds ratios of SVS per 1 SD increase in genetically predicted folate and vitamin B6 levels were 0.49 (95% CI, 0.34-0.71; p = 1.3 × 10-4 ) and 0.70 (95% CI, 0.52-0.94; p = 0.02), respectively. Genetically higher vitamin B12 levels were not associated with any stroke subtype. INTERPRETATION: These findings suggest that any effect of homocysteine-lowering treatment in preventing stroke will be confined to the SVS subtype. Whether genetic variants at or near the MTHFR and MUT genes influence SVS risk through pathways other than homocysteine levels and downstream effects require further investigation. Ann Neurol 2019;85:495-501.
引用
- Larsson SC, Traylor M, Markus HS, et al. Homocysteine and small vessel stroke: A mendelian randomization analysis. Ann Neurol. 2019. PMID: 30785218. doi:10.1002/ana.25440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。